MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4
Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with...
Gespeichert in:
Veröffentlicht in: | Autophagy 2020-04, Vol.16 (4), p.683-697 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 697 |
---|---|
container_issue | 4 |
container_start_page | 683 |
container_title | Autophagy |
container_volume | 16 |
creator | Wu, Hongkun Liu, Chang Yang, Qingyuan Xin, Chengde Du, Juan Sun, Fenyong Zhou, Lin |
description | Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with the aberrant autophagy in various human cancers. However, to date, few miRNAs have been reported to directly modulate autophagy in the pathobiology of MM. In this study, we investigated the role of MIR145-3p (microRNA 145-3p) in MM, with focus on cellular processes autophagy and cell death. Our results provided evidence that downregulation of MIR145-3p expression was associated with disease progression in human MM. MIR145-3p triggered autophagic flux through direct targeting of HDAC4 (histone deacetylase 4) in MM cells, leading to enhanced apoptosis. Silencing HDAC4 recapitulated the effects of MIR145-3p, whereas enforced expression of HDAC4 abrogated the effects of MIR145-3p. Furthermore, we showed that suppression of HDAC4 by MIR145-3p resulted in upregulation of the pro-apoptotic protein BCL2L11 and caused MTORC1 inactivation, which in turn led to enhanced autophagy and cell death. Importantly, we demonstrated that MIR145-3p mimic could potentiate the anti-MM activity of bortezomib in both in vitro and in vivo experiments. Overall, our findings indicate that MIR145-3p exerted a tumor suppression function in MM by inducing autophagic cell death and suggest that MIR145-3p-based targeted therapy would represent a novel strategy for MM treatment.
Abbreviations: 3-MA: 3-methyladenine; 3ʹ-UTR: 3ʹ-untranslated region; 7-AAD: 7-aminoactinomycin D; ACTB: actin beta; ANXA5: annexin A5; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; BAF: bafilomycin A
1
; BCL2L11: BCL2 like 11; Bort: bortezomib; CASP3: caspase 3; CCK-8: Cell Counting Kit-8; CQ: chloroquine; Ct: threshold cycle; ctrl: control; DAPI: 4ʹ,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HDAC4: histone deacetylase 4; ISS: International Staging System; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; miRNAs: microRNAs; MIR145-3p: microRNA 145-3p; MM: multiple myeloma; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PCs: plasma cells; PFS: progression-free survival; qRT-PCR: quantitative reverse transcription PCR; RPS6KB1: ribo |
doi_str_mv | 10.1080/15548627.2019.1635380 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7138223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248379913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-131a9738556079a3f5c2b6a45e05e34f8b976aa7d6ff8ad52b34e7df4cdb75c53</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EoqXwE0A-csnijzh2LohqKbRSUaUKztYkcbJGsR1spyj8-ma12xVcONkeP_POSA9CbynZUKLIBypEqSomN4zQekMrLrgiz9D5vl6o9fn8dGfyDL1K6SchvFI1e4nOOGUlo6w-R8O3m3taioJPeIrBhWwShjmHaQfDgsF32Pgd-HYtNyFm8yc42-BkfLLZPti8YOuxm8dsp9Fgt5gxOMDNgjPEwWTrB3z9-XJbvkYvehiTeXM8L9CPL1fft9fF7d3Xm-3lbdFyXuWCcgq15EqIisgaeC9a1lRQCkOE4WWvmlpWALKr-l5BJ1jDSyO7vmy7RopW8Av08ZA7zY0zXWt8jjDqKVoHcdEBrP73x9udHsKDlpQrxvga8P4YEMOv2aSsnU2tGUfwJsxJM1YqLuua7lFxQNsYUoqmP42hRO8l6SdJei9JHyWtfe_-3vHU9WRlBT4dAOv7EB38DnHsdIZlDLGPqw2bVvi_Mx4B9dii0Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2248379913</pqid></control><display><type>article</type><title>MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wu, Hongkun ; Liu, Chang ; Yang, Qingyuan ; Xin, Chengde ; Du, Juan ; Sun, Fenyong ; Zhou, Lin</creator><creatorcontrib>Wu, Hongkun ; Liu, Chang ; Yang, Qingyuan ; Xin, Chengde ; Du, Juan ; Sun, Fenyong ; Zhou, Lin</creatorcontrib><description>Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with the aberrant autophagy in various human cancers. However, to date, few miRNAs have been reported to directly modulate autophagy in the pathobiology of MM. In this study, we investigated the role of MIR145-3p (microRNA 145-3p) in MM, with focus on cellular processes autophagy and cell death. Our results provided evidence that downregulation of MIR145-3p expression was associated with disease progression in human MM. MIR145-3p triggered autophagic flux through direct targeting of HDAC4 (histone deacetylase 4) in MM cells, leading to enhanced apoptosis. Silencing HDAC4 recapitulated the effects of MIR145-3p, whereas enforced expression of HDAC4 abrogated the effects of MIR145-3p. Furthermore, we showed that suppression of HDAC4 by MIR145-3p resulted in upregulation of the pro-apoptotic protein BCL2L11 and caused MTORC1 inactivation, which in turn led to enhanced autophagy and cell death. Importantly, we demonstrated that MIR145-3p mimic could potentiate the anti-MM activity of bortezomib in both in vitro and in vivo experiments. Overall, our findings indicate that MIR145-3p exerted a tumor suppression function in MM by inducing autophagic cell death and suggest that MIR145-3p-based targeted therapy would represent a novel strategy for MM treatment.
Abbreviations: 3-MA: 3-methyladenine; 3ʹ-UTR: 3ʹ-untranslated region; 7-AAD: 7-aminoactinomycin D; ACTB: actin beta; ANXA5: annexin A5; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; BAF: bafilomycin A
1
; BCL2L11: BCL2 like 11; Bort: bortezomib; CASP3: caspase 3; CCK-8: Cell Counting Kit-8; CQ: chloroquine; Ct: threshold cycle; ctrl: control; DAPI: 4ʹ,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HDAC4: histone deacetylase 4; ISS: International Staging System; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; miRNAs: microRNAs; MIR145-3p: microRNA 145-3p; MM: multiple myeloma; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PCs: plasma cells; PFS: progression-free survival; qRT-PCR: quantitative reverse transcription PCR; RPS6KB1: ribosomal protein S6 kinase B1; SD: standard deviation; siRNA: small interfering RNA; SQSTM1: sequestosome 1; STV: starvation; TUBB: tubulin beta class I.</description><identifier>ISSN: 1554-8627</identifier><identifier>EISSN: 1554-8635</identifier><identifier>DOI: 10.1080/15548627.2019.1635380</identifier><identifier>PMID: 31242129</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Animals ; Apoptosis ; Apoptosis - drug effects ; Apoptosis - genetics ; autophagic cell death ; autophagy ; Autophagy - drug effects ; Autophagy - physiology ; bortezomib ; Bortezomib - metabolism ; Bortezomib - pharmacology ; Down-Regulation - drug effects ; HDAC4 ; Histone Deacetylases - drug effects ; Histone Deacetylases - genetics ; Humans ; Lysosomes - drug effects ; Lysosomes - metabolism ; Mice ; MicroRNAs - drug effects ; MicroRNAs - genetics ; MIR145-3p ; multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - genetics ; Multiple Myeloma - pathology ; Repressor Proteins - drug effects ; Repressor Proteins - genetics ; Research Paper ; Up-Regulation - drug effects</subject><ispartof>Autophagy, 2020-04, Vol.16 (4), p.683-697</ispartof><rights>2019 Informa UK Limited, trading as Taylor & Francis Group 2019</rights><rights>2019 Informa UK Limited, trading as Taylor & Francis Group 2019 Informa UK Limited, trading as Taylor & Francis Group</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-131a9738556079a3f5c2b6a45e05e34f8b976aa7d6ff8ad52b34e7df4cdb75c53</citedby><cites>FETCH-LOGICAL-c336t-131a9738556079a3f5c2b6a45e05e34f8b976aa7d6ff8ad52b34e7df4cdb75c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138223/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138223/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31242129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Hongkun</creatorcontrib><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Yang, Qingyuan</creatorcontrib><creatorcontrib>Xin, Chengde</creatorcontrib><creatorcontrib>Du, Juan</creatorcontrib><creatorcontrib>Sun, Fenyong</creatorcontrib><creatorcontrib>Zhou, Lin</creatorcontrib><title>MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4</title><title>Autophagy</title><addtitle>Autophagy</addtitle><description>Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with the aberrant autophagy in various human cancers. However, to date, few miRNAs have been reported to directly modulate autophagy in the pathobiology of MM. In this study, we investigated the role of MIR145-3p (microRNA 145-3p) in MM, with focus on cellular processes autophagy and cell death. Our results provided evidence that downregulation of MIR145-3p expression was associated with disease progression in human MM. MIR145-3p triggered autophagic flux through direct targeting of HDAC4 (histone deacetylase 4) in MM cells, leading to enhanced apoptosis. Silencing HDAC4 recapitulated the effects of MIR145-3p, whereas enforced expression of HDAC4 abrogated the effects of MIR145-3p. Furthermore, we showed that suppression of HDAC4 by MIR145-3p resulted in upregulation of the pro-apoptotic protein BCL2L11 and caused MTORC1 inactivation, which in turn led to enhanced autophagy and cell death. Importantly, we demonstrated that MIR145-3p mimic could potentiate the anti-MM activity of bortezomib in both in vitro and in vivo experiments. Overall, our findings indicate that MIR145-3p exerted a tumor suppression function in MM by inducing autophagic cell death and suggest that MIR145-3p-based targeted therapy would represent a novel strategy for MM treatment.
Abbreviations: 3-MA: 3-methyladenine; 3ʹ-UTR: 3ʹ-untranslated region; 7-AAD: 7-aminoactinomycin D; ACTB: actin beta; ANXA5: annexin A5; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; BAF: bafilomycin A
1
; BCL2L11: BCL2 like 11; Bort: bortezomib; CASP3: caspase 3; CCK-8: Cell Counting Kit-8; CQ: chloroquine; Ct: threshold cycle; ctrl: control; DAPI: 4ʹ,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HDAC4: histone deacetylase 4; ISS: International Staging System; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; miRNAs: microRNAs; MIR145-3p: microRNA 145-3p; MM: multiple myeloma; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PCs: plasma cells; PFS: progression-free survival; qRT-PCR: quantitative reverse transcription PCR; RPS6KB1: ribosomal protein S6 kinase B1; SD: standard deviation; siRNA: small interfering RNA; SQSTM1: sequestosome 1; STV: starvation; TUBB: tubulin beta class I.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - genetics</subject><subject>autophagic cell death</subject><subject>autophagy</subject><subject>Autophagy - drug effects</subject><subject>Autophagy - physiology</subject><subject>bortezomib</subject><subject>Bortezomib - metabolism</subject><subject>Bortezomib - pharmacology</subject><subject>Down-Regulation - drug effects</subject><subject>HDAC4</subject><subject>Histone Deacetylases - drug effects</subject><subject>Histone Deacetylases - genetics</subject><subject>Humans</subject><subject>Lysosomes - drug effects</subject><subject>Lysosomes - metabolism</subject><subject>Mice</subject><subject>MicroRNAs - drug effects</subject><subject>MicroRNAs - genetics</subject><subject>MIR145-3p</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - pathology</subject><subject>Repressor Proteins - drug effects</subject><subject>Repressor Proteins - genetics</subject><subject>Research Paper</subject><subject>Up-Regulation - drug effects</subject><issn>1554-8627</issn><issn>1554-8635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EoqXwE0A-csnijzh2LohqKbRSUaUKztYkcbJGsR1spyj8-ma12xVcONkeP_POSA9CbynZUKLIBypEqSomN4zQekMrLrgiz9D5vl6o9fn8dGfyDL1K6SchvFI1e4nOOGUlo6w-R8O3m3taioJPeIrBhWwShjmHaQfDgsF32Pgd-HYtNyFm8yc42-BkfLLZPti8YOuxm8dsp9Fgt5gxOMDNgjPEwWTrB3z9-XJbvkYvehiTeXM8L9CPL1fft9fF7d3Xm-3lbdFyXuWCcgq15EqIisgaeC9a1lRQCkOE4WWvmlpWALKr-l5BJ1jDSyO7vmy7RopW8Av08ZA7zY0zXWt8jjDqKVoHcdEBrP73x9udHsKDlpQrxvga8P4YEMOv2aSsnU2tGUfwJsxJM1YqLuua7lFxQNsYUoqmP42hRO8l6SdJei9JHyWtfe_-3vHU9WRlBT4dAOv7EB38DnHsdIZlDLGPqw2bVvi_Mx4B9dii0Q</recordid><startdate>20200402</startdate><enddate>20200402</enddate><creator>Wu, Hongkun</creator><creator>Liu, Chang</creator><creator>Yang, Qingyuan</creator><creator>Xin, Chengde</creator><creator>Du, Juan</creator><creator>Sun, Fenyong</creator><creator>Zhou, Lin</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200402</creationdate><title>MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4</title><author>Wu, Hongkun ; Liu, Chang ; Yang, Qingyuan ; Xin, Chengde ; Du, Juan ; Sun, Fenyong ; Zhou, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-131a9738556079a3f5c2b6a45e05e34f8b976aa7d6ff8ad52b34e7df4cdb75c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - genetics</topic><topic>autophagic cell death</topic><topic>autophagy</topic><topic>Autophagy - drug effects</topic><topic>Autophagy - physiology</topic><topic>bortezomib</topic><topic>Bortezomib - metabolism</topic><topic>Bortezomib - pharmacology</topic><topic>Down-Regulation - drug effects</topic><topic>HDAC4</topic><topic>Histone Deacetylases - drug effects</topic><topic>Histone Deacetylases - genetics</topic><topic>Humans</topic><topic>Lysosomes - drug effects</topic><topic>Lysosomes - metabolism</topic><topic>Mice</topic><topic>MicroRNAs - drug effects</topic><topic>MicroRNAs - genetics</topic><topic>MIR145-3p</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - pathology</topic><topic>Repressor Proteins - drug effects</topic><topic>Repressor Proteins - genetics</topic><topic>Research Paper</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Hongkun</creatorcontrib><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Yang, Qingyuan</creatorcontrib><creatorcontrib>Xin, Chengde</creatorcontrib><creatorcontrib>Du, Juan</creatorcontrib><creatorcontrib>Sun, Fenyong</creatorcontrib><creatorcontrib>Zhou, Lin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autophagy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Hongkun</au><au>Liu, Chang</au><au>Yang, Qingyuan</au><au>Xin, Chengde</au><au>Du, Juan</au><au>Sun, Fenyong</au><au>Zhou, Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4</atitle><jtitle>Autophagy</jtitle><addtitle>Autophagy</addtitle><date>2020-04-02</date><risdate>2020</risdate><volume>16</volume><issue>4</issue><spage>683</spage><epage>697</epage><pages>683-697</pages><issn>1554-8627</issn><eissn>1554-8635</eissn><abstract>Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with the aberrant autophagy in various human cancers. However, to date, few miRNAs have been reported to directly modulate autophagy in the pathobiology of MM. In this study, we investigated the role of MIR145-3p (microRNA 145-3p) in MM, with focus on cellular processes autophagy and cell death. Our results provided evidence that downregulation of MIR145-3p expression was associated with disease progression in human MM. MIR145-3p triggered autophagic flux through direct targeting of HDAC4 (histone deacetylase 4) in MM cells, leading to enhanced apoptosis. Silencing HDAC4 recapitulated the effects of MIR145-3p, whereas enforced expression of HDAC4 abrogated the effects of MIR145-3p. Furthermore, we showed that suppression of HDAC4 by MIR145-3p resulted in upregulation of the pro-apoptotic protein BCL2L11 and caused MTORC1 inactivation, which in turn led to enhanced autophagy and cell death. Importantly, we demonstrated that MIR145-3p mimic could potentiate the anti-MM activity of bortezomib in both in vitro and in vivo experiments. Overall, our findings indicate that MIR145-3p exerted a tumor suppression function in MM by inducing autophagic cell death and suggest that MIR145-3p-based targeted therapy would represent a novel strategy for MM treatment.
Abbreviations: 3-MA: 3-methyladenine; 3ʹ-UTR: 3ʹ-untranslated region; 7-AAD: 7-aminoactinomycin D; ACTB: actin beta; ANXA5: annexin A5; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; BAF: bafilomycin A
1
; BCL2L11: BCL2 like 11; Bort: bortezomib; CASP3: caspase 3; CCK-8: Cell Counting Kit-8; CQ: chloroquine; Ct: threshold cycle; ctrl: control; DAPI: 4ʹ,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HDAC4: histone deacetylase 4; ISS: International Staging System; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; miRNAs: microRNAs; MIR145-3p: microRNA 145-3p; MM: multiple myeloma; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PCs: plasma cells; PFS: progression-free survival; qRT-PCR: quantitative reverse transcription PCR; RPS6KB1: ribosomal protein S6 kinase B1; SD: standard deviation; siRNA: small interfering RNA; SQSTM1: sequestosome 1; STV: starvation; TUBB: tubulin beta class I.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>31242129</pmid><doi>10.1080/15548627.2019.1635380</doi><tpages>15</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1554-8627 |
ispartof | Autophagy, 2020-04, Vol.16 (4), p.683-697 |
issn | 1554-8627 1554-8635 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7138223 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Animals Apoptosis Apoptosis - drug effects Apoptosis - genetics autophagic cell death autophagy Autophagy - drug effects Autophagy - physiology bortezomib Bortezomib - metabolism Bortezomib - pharmacology Down-Regulation - drug effects HDAC4 Histone Deacetylases - drug effects Histone Deacetylases - genetics Humans Lysosomes - drug effects Lysosomes - metabolism Mice MicroRNAs - drug effects MicroRNAs - genetics MIR145-3p multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - pathology Repressor Proteins - drug effects Repressor Proteins - genetics Research Paper Up-Regulation - drug effects |
title | MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T14%3A50%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MIR145-3p%20promotes%20autophagy%20and%20enhances%20bortezomib%20sensitivity%20in%20multiple%20myeloma%20by%20targeting%20HDAC4&rft.jtitle=Autophagy&rft.au=Wu,%20Hongkun&rft.date=2020-04-02&rft.volume=16&rft.issue=4&rft.spage=683&rft.epage=697&rft.pages=683-697&rft.issn=1554-8627&rft.eissn=1554-8635&rft_id=info:doi/10.1080/15548627.2019.1635380&rft_dat=%3Cproquest_pubme%3E2248379913%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2248379913&rft_id=info:pmid/31242129&rfr_iscdi=true |